<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611412369</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611412369</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Role of Factor V Leiden in Adult Patients With Venous Thromboembolism: A Meta-Analysis of Published Studies from Turkey</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Eroglu</surname>
<given-names>Aydan</given-names>
</name>
<xref ref-type="aff" rid="aff1-1076029611412369">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029611412369"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sertkaya</surname>
<given-names>Durdu</given-names>
</name>
<xref ref-type="aff" rid="aff2-1076029611412369">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akar</surname>
<given-names>Nejat</given-names>
</name>
<xref ref-type="aff" rid="aff3-1076029611412369">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1076029611412369"><label>1</label>General Surgery, Ankara University Medical School, Ankara, Turkey</aff>
<aff id="aff2-1076029611412369"><label>2</label>Faculty of Science, Statistics Section, Hacettepe University, Beytepe/Ankara, Turkey</aff>
<aff id="aff3-1076029611412369"><label>3</label>Pediatrics, TOBB-ETU University Hospital</aff>
<author-notes>
<corresp id="corresp1-1076029611412369">Aydan Eroglu, Department of General Surgery, Ankara University Medical School, Cebeci Kampus, Dikimevi, 06590, Ankara, Turkey Email:<email>aydaneroglu@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>1</issue>
<fpage>40</fpage>
<lpage>44</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Factor V Leiden (FVL) is the most common inherited risk factor for venous thromboembolism (VTE). The frequency of FVL in patients with VTE has been reported from different parts of Turkey. A meta-analysis was performed to estimate the risk of VTE associated with FVL in Turkish population. Published studies were retrieved from Pubmed and Science Citation Index/Expanded. We selected studies comparing the prevalence of FVL in patients with VTE with controls. The analysis was performed by the software comprehensive meta-analysis. The analysis consisted of 10 studies including 1202 patients with VTE and 1283 controls. The pooled frequency of FVL was significantly higher in patients with VTE (22.8%) than controls (7.6%). The pooled odds ratio (OR) was 3.4 (95% confidence interval [CI], 2.6-4.5). The study showed homogeneity (<italic>Q</italic> value, 9.955). No publication bias was observed in any comparison model. Our meta-analysis showed an association of FVL with VTE in Turkey.</p>
</abstract>
<kwd-group>
<kwd>factor V Leiden</kwd>
<kwd>venous thromboembolism</kwd>
<kwd>Turkey</kwd>
<kwd>Turkish population</kwd>
</kwd-group><custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/Febraury 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1076029611412369">
<title>Introduction</title>
<p>Factor V Leiden (FVL) causing activated protein C resistance is the most common inherited risk factor for venous thromboembolism (VTE).<sup><xref ref-type="bibr" rid="bibr1-1076029611412369">1</xref>,<xref ref-type="bibr" rid="bibr2-1076029611412369">2</xref></sup> Factor V Leiden increases the thrombosis risk approximately by 7-fold. Heterozygosity for FVL causes 5- to 10-fold increased risk of VTE, whereas the risk of homozygosity is 80- to 100-fold higher than the normal population.<sup><xref ref-type="bibr" rid="bibr1-1076029611412369">1</xref>,<xref ref-type="bibr" rid="bibr2-1076029611412369">2</xref></sup>
</p>
<p>The frequency of FVL mutation shows a geographic distribution. The high prevalence of FVL is seen in Middle East, Southern Europe, and Mediterranean region; however, it is not observed in some populations like Chinese.<sup><xref ref-type="bibr" rid="bibr3-1076029611412369">3</xref><xref ref-type="bibr" rid="bibr4-1076029611412369"/><xref ref-type="bibr" rid="bibr5-1076029611412369"/>–<xref ref-type="bibr" rid="bibr6-1076029611412369">6</xref></sup> In several studies, the prevalence of FVL in Turkish people with VTE has been reported from different parts of Turkey. Factor V Leiden frequency in healthy Turkish population is 7.9% (range, 3.5%-15%).<sup><xref ref-type="bibr" rid="bibr7-1076029611412369">7</xref></sup> We performed a meta-analysis to estimate the risk of VTE associated with FVL in Turkish population.</p>
</sec>
<sec id="section2-1076029611412369">
<title>Materials and Methods</title>
<p>The data were compiled from Medline/Pubmed and Science Citation Index/Expanded databases. The keywords used for search were “factor V Leiden,” “factor V 1691 G-A,” “FVL,” “mutation,” “polymorphism,” “venous thrombosis,” “pulmonary embolism,” “Turkey,” and “Turkish population.”</p>
<p>Eligible studies fulfilled the following criteria: retrospective or prospective cohort case–control studies, with sufficient data to estimate an odds ratio (OR) with 95% confidence interval (CI), the study with 2 arms comparing patients with idiopathic VTE to those without VTE. For overlapping and republished studies by the same investigators, we selected the most recent ones with large sample sizes or available genotype data. Case reports and the studies including pediatric patients were excluded from the meta-analysis. Besides, patients with specific disease such as cancer, the Behcet disease, and the Crohn disease were excluded from the analysis (<xref ref-type="fig" rid="fig1-1076029611412369">Figure 1</xref>).</p>
<fig id="fig1-1076029611412369" position="float">
<label>Figure 1.</label>
<caption>
<p>Summary of trial search and eligibility process.</p>
</caption>
<graphic xlink:href="10.1177_1076029611412369-fig1.tif"/>
</fig>
<p>Meta-analysis was performed to obtain a full and comprehensive summary of the related studies. The correlation coefficients (<italic>r</italic>) were combined using the fixed- and random-effects models. Heterogeneity of the studies was evaluated by the homogeneity test (<italic>Q</italic>). If homogeneity is found between the studies, the outcome of a fixed-effects model is performed. In the event of a heterogeneity, it is appropriate to use the result of a random-effects model.<sup><xref ref-type="bibr" rid="bibr8-1076029611412369">8</xref></sup>
</p>
<p>Heterogeneity assumption was checked by the chi-square-based <italic>Q</italic> test. The pooled OR was calculated through the fixed-effects model. Begg funnel plot and Egger linear regression test were used to assess the potential publication bias of the literature.<sup><xref ref-type="bibr" rid="bibr9-1076029611412369">9</xref></sup> <italic>P</italic> &lt; .05 was considered the representative of statistically significant publication bias. The analyses were performed using the software Comprehensive Meta-Analysis, version 2.2 (Biostat, Englewood, NJ).</p>
</sec>
<sec id="section3-1076029611412369">
<title>Results</title>
<p>A total of 10 studies<sup><xref ref-type="bibr" rid="bibr10-1076029611412369">10</xref><xref ref-type="bibr" rid="bibr11-1076029611412369"/><xref ref-type="bibr" rid="bibr12-1076029611412369"/><xref ref-type="bibr" rid="bibr13-1076029611412369"/><xref ref-type="bibr" rid="bibr14-1076029611412369"/><xref ref-type="bibr" rid="bibr15-1076029611412369"/><xref ref-type="bibr" rid="bibr16-1076029611412369"/><xref ref-type="bibr" rid="bibr17-1076029611412369"/><xref ref-type="bibr" rid="bibr18-1076029611412369"/>–<xref ref-type="bibr" rid="bibr19-1076029611412369">19</xref></sup> including 1202 patients with VTE and 1283 control cases were involved in this meta-analysis. <xref ref-type="table" rid="table1-1076029611412369">Table 1</xref> summarizes the characteristics of each study. The pooled frequency of FVL was significantly higher in patients with VTE (22.8%) than the control participants (7.6%). The main results of meta-analysis and the forests of the studies are shown in <xref ref-type="fig" rid="fig2-1076029611412369">Figure 2</xref>. When the homogeneity test was performed, the study was found to be homogeneous. Therefore, the fixed-effects model was used. The <italic>Q</italic> value was 9.955 (<italic>P</italic> = .354). The pooled OR was 3.4 (95% CI, 2.6-4.5; <italic>P</italic> &lt; .0001). In addition, no evidence of the publication bias was observed in any comparison model. As shown in <xref ref-type="fig" rid="fig3-1076029611412369">Figure 3</xref>, the plot of the 10 studies had a funnel image and therefore there was no publication bias. Possible publication bias was assessed by the rank correlation test and yielded <italic>P</italic> = .17, which reveals that there was no publication bias at the 95% CI. Besides, the Begg test (<italic>P</italic> = .21, with continuity correction) and the Egger test (<italic>P</italic> = .29) also revealed no publication bias at the 95% CI.</p>
<table-wrap id="table1-1076029611412369" position="float">
<label>Table 1.</label>
<caption>
<p>Characteristics of Study Participants</p>
</caption>
<graphic alternate-form-of="table1-1076029611412369" xlink:href="10.1177_1076029611412369-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
</th>
<th>
</th>
<th align="center" colspan="3">Patients with VTE</th>
<th align="center" colspan="3">Control Participants</th>
</tr>
<tr>
<th>
</th>
<th>
</th>
<th>
</th>
<th align="center" colspan="3">FVL Mutation</th>
<th align="center" colspan="3">FVL Mutation</th>
</tr>
<tr>
<th>Study</th>
<th>Ref Number</th>
<th>Year</th>
<th>Positive (%)</th>
<th>Negative (%)</th>
<th>Total</th>
<th>Positive (%)</th>
<th>Negative (%)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akar et al<sup>a</sup>
</td>
<td>10</td>
<td>2000</td>
<td>16 (23.5)</td>
<td>52 (76.5)</td>
<td>68</td>
<td>4 (6.06)</td>
<td>62 (93.04)</td>
<td>66</td>
</tr>
<tr>
<td>Erkekol et al</td>
<td>11</td>
<td>2006</td>
<td>10 (15.6)</td>
<td>54 (84.4)</td>
<td>64</td>
<td>6 (9.4)</td>
<td>58 (90.6)</td>
<td>66</td>
</tr>
<tr>
<td>Dolek et al</td>
<td>12</td>
<td>2007</td>
<td>76 (28.2)</td>
<td>194 (71.8)</td>
<td>270</td>
<td>4 (3.5)</td>
<td>100 (96.5)</td>
<td>114</td>
</tr>
<tr>
<td>Kalkanli et al</td>
<td>13</td>
<td>2006</td>
<td>15 (24.6)</td>
<td>46 (75.4)</td>
<td>61</td>
<td>29 (9.1)</td>
<td>291 (90.9)</td>
<td>320</td>
</tr>
<tr>
<td>Altinisik et al</td>
<td>14</td>
<td>2008</td>
<td>3 (6)</td>
<td>47 (94)</td>
<td>50</td>
<td>0</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Okumus et al</td>
<td>15</td>
<td>2008</td>
<td>44 (23)</td>
<td>147 (77)</td>
<td>191</td>
<td>17 (8.9)</td>
<td>174 (91.1)</td>
<td>191</td>
</tr>
<tr>
<td>Gurgey et al</td>
<td>16</td>
<td>2001</td>
<td>45 (30.7)</td>
<td>101 (69.3)</td>
<td>146</td>
<td>6 (7.4)</td>
<td>75 (92.6)</td>
<td>81</td>
</tr>
<tr>
<td>Akar et al<sup>b</sup>
</td>
<td>17</td>
<td>2000</td>
<td>26 (20.1)</td>
<td>103 (79.9)</td>
<td>129</td>
<td>15 (10.4)</td>
<td>129 (89.6)</td>
<td>144</td>
</tr>
<tr>
<td>Oguzulgen et al</td>
<td>18</td>
<td>2009</td>
<td>30 (21)</td>
<td>113 (79)</td>
<td>143</td>
<td>14 (7.7)</td>
<td>167 (92.3)</td>
<td>181</td>
</tr>
<tr>
<td>Kupeli et al</td>
<td>19</td>
<td>2010</td>
<td>9 (11.3)</td>
<td>71 (88.7)</td>
<td>80</td>
<td>2 (2.1)</td>
<td>95 (97.9)</td>
<td>97</td>
</tr>
<tr>
<td>Total number of cases</td>
<td>
</td>
<td>
</td>
<td>274 (22.8)</td>
<td>928 (77.2)</td>
<td>1202</td>
<td>97 (7.6)</td>
<td>1186 (92.4)</td>
<td>1283</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029611412369">
<p>Abbreviations: FVL, factor V Leiden; VTE, venous thromboembolism.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-1076029611412369" position="float">
<label>Figure 2.</label>
<caption>
<p>Results of meta-analysis based on a quality score (pooled estimate and 95% confidence intervals).</p>
</caption>
<graphic xlink:href="10.1177_1076029611412369-fig2.tif"/>
</fig>
<fig id="fig3-1076029611412369" position="float">
<label>Figure 3.</label>
<caption>
<p>Funnel plot of 10 studies including log odds ratio.</p>
</caption>
<graphic xlink:href="10.1177_1076029611412369-fig3.tif"/>
</fig>
</sec>
<sec id="section4-1076029611412369">
<title>Discussion</title>
<p>The frequency of FVL has been reported in different surveys carried out in many countries, depending on the geographical location and the ethnic background of the population. Its frequency is reported to be 2% to 15% and the highest prevalence rates are seen in Mediterranean countries.<sup><xref ref-type="bibr" rid="bibr4-1076029611412369">4</xref>,<xref ref-type="bibr" rid="bibr6-1076029611412369">6</xref></sup> Factor V Leiden mutation has been estimated to be approximately 15 000 to 30 000 years ago during the Neolithic period. Lucotte and Mercier proposed that FVL in Europe was expanded from Turkey, Anatolia, which lies central to 3 continents and is at crossroads of several numbers of civilizations.<sup><xref ref-type="bibr" rid="bibr6-1076029611412369">6</xref></sup> The prevalence of FVL in Turkish people with VTE and healthy Turkish population has been reported from different parts of Turkey.<sup><xref ref-type="bibr" rid="bibr7-1076029611412369">7</xref>,<xref ref-type="bibr" rid="bibr20-1076029611412369">20</xref></sup> The existence of mutation in Anatolia is expected to be high. This situation has been recently supported by a study by Alakoc et al, indicating the presence of FVL in Urartians.<sup><xref ref-type="bibr" rid="bibr21-1076029611412369">21</xref></sup>
</p>
<p>There exist limited information about why genetic diseases are present in a high frequency rather than not being eliminated by natural selection.<sup><xref ref-type="bibr" rid="bibr22-1076029611412369">22</xref></sup> Most probably, the answer lies in the survival advantage caused by the mutation. Even a small increase in the frequency of FVL for 1 generation would have yielded a significant difference through hundreds of generations.<sup><xref ref-type="bibr" rid="bibr23-1076029611412369">23</xref></sup>
</p>
<p>Turkish population seems to be a very good candidate to study the possible effects of FVL on VTE with its significantly high FVL. We therefore performed the meta-analysis of 10 eligible studies including 1202 cases and 1283 controls for a better evaluation of this association in Turkish population. When all studies were pooled together, our results demonstrated that FVL is associated with VTE development. Our meta-analysis also showed that pooled frequency of FVL in healthy Turkish people is 7.6%. As a conclusion, we can hypothesize that every individual with VTE should be screened for FVL whether or not carrying a risk factor.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1076029611412369">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="financial-disclosure" id="fn2-1076029611412369">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611412369">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertina</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Koelman</surname>
<given-names>BPC</given-names>
</name>
<name>
<surname>Koster</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation in blood coagulation factor V associated with resistance to activated protein C</article-title>. <source>Nature</source>. <year>1994</year>;<volume>369</volume>(<issue>6475</issue>):<fpage>64</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611412369">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosendaal</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Koster</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vandenbroucke</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Reitsma</surname>
<given-names>PH</given-names>
</name>
</person-group>. <article-title>High risk of thrombosis in patients homogygous for factor V Leiden (activated protein C resistance)</article-title>. <source>Blood</source>. <year>1995</year>;<volume>85</volume>(<issue>6</issue>):<fpage>1504</fpage>–<lpage>1508</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611412369">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rees</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clegg</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>World distribution of factor V Leiden</article-title>. <source>Lancet</source>. <year>1995</year>;<volume>346</volume>(<issue>8983</issue>):<fpage>1133</fpage>–<lpage>1134</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611412369">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irani-Hakime</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tamim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kreidy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Almawi</surname>
<given-names>WY</given-names>
</name>
</person-group>. <article-title>The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanase</article-title>. <source>Am J Hematol</source>. <year>2000</year>;<volume>65</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611412369">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Bourke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>CK</given-names>
</name>
<etal/>
</person-group>. <article-title>Lack of activated protein C resistance in healthy Hong-Kong Chinese blood donors-correlation with absence of Arg506-Gln mutation of factor V gene</article-title>. <source>Thromb Haemost</source>. <year>1996</year>;<volume>75</volume>(<issue>3</issue>):<fpage>522</fpage>–<lpage>523</lpage>.</citation>
</ref>
<ref id="bibr6-1076029611412369">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucotte</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mercier</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Population genetics of factor V Leiden in Europe</article-title>. <source>Blood Cells Mol Dis</source>. <year>2001</year>;<volume>27</volume>(<issue>2</issue>):<fpage>362</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr7-1076029611412369">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Factor V 1691 G-A mutation distribution in a healthy Turkish population</article-title>. <source>Turk J Hematol</source>. <year>2009</year>;<volume>26</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611412369">
<label>8</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Sutton</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Sheldon</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>F</given-names>
</name>
</person-group>.
<article-title>Methods for meta-analysis in medical research</article-title>.  In: <person-group person-group-type="editor">
<name>
<surname>Cressie</surname>
<given-names>NAC</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>IM</given-names>
</name>
</person-group>. (Eds.), <source>Assessing Between Study Heterogeneity, Publication Bias, Study Quality, and Sensitivity Analysis</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley and Sons</publisher-name>; <year>2000</year>:<fpage>37</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr9-1076029611412369">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Minder</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Bias in meta-analysis detected by a single, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>;<volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr10-1076029611412369">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Akçay</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Avcu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yalcin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cin</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Effect of metylenetetrahyrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients</article-title>. <source>Thromb Res</source>. <year>2000</year>;<volume>97</volume>(<issue>3</issue>):<fpage>163</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr11-1076029611412369">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erkekol</surname>
<given-names>FO</given-names>
</name>
<name>
<surname>Ulu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Numanoglu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>High plasma levels of factor VIII: an important risk factor for isolated pulmonary embolism</article-title>. <source>Respirology</source>. <year>2006</year>;<volume>11</volume>(<issue>1</issue>):<fpage>70</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr12-1076029611412369">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolek</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eraslan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eroglu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2007</year>;<volume>13</volume>(<issue>4</issue>):<fpage>435</fpage>–<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr13-1076029611412369">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalkanli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ayyildiz</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tiftik</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Factor V Leiden mutation in venous thrombosis in southeast Turkey</article-title>. <source>Angiology</source>. <year>2006</year>;<volume>57</volume>(<issue>2</issue>):<fpage>193</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr14-1076029611412369">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altinisik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ates</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ulutin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cengiz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buyru</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Factor V Leiden, prothrombin G20210A, and protein C mutation frequency in Turkish venous thrombosis patients</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2008</year>;<volume>14</volume>(<issue>4</issue>):<fpage>415</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr15-1076029611412369">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okumus</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kiyan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Arseven</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: the role in different clinical manifestations of venous thromboembolism</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2008</year>;<volume>14</volume>(<issue>2</issue>):<fpage>168</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr16-1076029611412369">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurgey</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Egesel</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Two common thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis</article-title>. <source>Am J Hematol</source>. <year>2001</year>;<volume>67</volume>(<issue>2</issue>):<fpage>107</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr17-1076029611412369">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yılmaz</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Coexistence of factor V 1691 G-A and factor V 4070A-G mutation in Turkish thromboembolic patients</article-title>. <source>Am J hematol</source>. <year>2000</year>;<volume>65</volume>(<issue>1</issue>):<fpage>87</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr18-1076029611412369">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oguzulgen</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Yılmaz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Demirtas</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of plasminogen activator inhibitor-1 polymorphism, factor V Leiden, and prothrombin 20210 mutations in pulmonary thromboembolism</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2009</year>;<volume>15</volume>(<issue>1</issue>):<fpage>73</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr19-1076029611412369">
<label>19</label>
<citation citation-type="book">
<person-group person-group-type="author"><name><surname>Kupeli</surname><given-names>E</given-names></name><name><surname>Verdi</surname><given-names>H</given-names></name><name><surname>Simsek</surname><given-names>A</given-names></name><name><surname>Atac</surname><given-names>FB</given-names></name><name><surname>Eyupoglu</surname><given-names>FO.</given-names></name></person-group> <article-title>Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis</article-title>. <source>Clin Appl Thromb Hemost</source>.  <year>2010</year> <month>Nov</month> <day>15</day> <comment>(Epub ahead of print)</comment>.
</citation>
</ref>
<ref id="bibr20-1076029611412369">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbayram</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akgün</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Doğan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bektaş</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Öner</surname>
<given-names>AF</given-names>
</name>
</person-group>. <article-title>The prevalence of factor V 1691G-A mutation in Van Region of Turkey</article-title>. <source>Turk J Hematol</source>. <year>2010</year>;<volume>27</volume>(<issue>3</issue>):<fpage>211</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr21-1076029611412369">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dogan Alakoc</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Egin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Factor V Leiden in an Urartian, dating back to 1000 BC</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2010</year>;<volume>16</volume>(<issue>6</issue>):<fpage>679</fpage>–<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr22-1076029611412369">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flint</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Harding</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Clegg</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Boyce</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants</article-title>. <source>Hum Genet</source>. <year>1993</year>;<volume>91</volume>(<issue>2</issue>):<fpage>91</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr23-1076029611412369">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindqvist</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Dahlback</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Carriership of factor V Leiden and evolutionary selection advantage</article-title>. <source>Curr Med Chem</source>. <year>2008</year>;<volume>15</volume>(<issue>15</issue>):<fpage>1541</fpage>–<lpage>1544</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>